Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis

BACKGROUND: The use of regorafenib in the treatment of hepatocellular carcinoma (HCC) is widespread. Albumin-Bilirubin (ALBI) has been shown to be a potential prognostic marker for regorafenib treatment, but its prognostic value remains controversial. Therefore, we conducted a meta-analysis to inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Huilin, Cao, Dedong, Zhou, Dingjie, Zhao, Nan, Tang, Xixian, Shelat, Vishalkumar G., Samant, Hrishikesh, Satapathy, Sanjaya K., Tustumi, Francisco, Aprile, Giuseppe, He, Anbing, Xu, Ximing, Ge, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588229/
https://www.ncbi.nlm.nih.gov/pubmed/37858207
http://dx.doi.org/10.1186/s12885-023-11488-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588229/
https://www.ncbi.nlm.nih.gov/pubmed/37858207
http://dx.doi.org/10.1186/s12885-023-11488-9

Ejemplares similares